Evidence map›Paper›PMID 26233505›Full record

ArticleThe Journal of rheumatology2015

Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis.

Michelle J Ormseth, Joseph F Solus, Kasey C Vickers, Annette M Oeser, Paolo Raggi, C Michael Stein

Abstract readComparative Study
In one paragraph

Article in The Journal of rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. microRNAs as Biomarkers and Therapeutic Targets in Rheumatoid Arthritis.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michelle J Ormseth *Department of Medicine and Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN, USA.
Joseph F Solus *Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
Kasey C VickersDepartment of Medicine and Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Annette M OeserDepartment of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
Paolo RaggiDepartment of Medicine and Division of Cardiology, University of Alberta, Edmonton, Canada.
C Michael SteinDepartment of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
University of Alberta · CA

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Non-coding RNA & Bioinformatics CoreP01HL116263 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VICKERS, KASEY C · 2014 to 2025
$24.7M
Vanderbilt Multidisciplinary Clinical Research CenterP60AR056116 · NIAMS · VANDERBILT UNIVERSITY · PI STEIN, CHARLES M. · 2008 to 2012
$6.2M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)KL2TR000446 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$2.8M
HDL-microRNA Intercellular Communication in AtherosclerosisR01HL128996 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VICKERS, KASEY C · 2015 to 2019
$2.3M
Functional Impact of HDL transport of miRNA in rheumatoid arthritisK23AR068443 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ORMSETH, MICHELLE JANE · 2015 to 2016
$184k
NCATS NIH HHS KL2 TR000446NCATS NIH HHS KL2TR000446NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1TR000445NHLBI NIH HHS P01 HL116263NHLBI NIH HHS P01HL116263NHLBI NIH HHS R01 HL128996NIAMS NIH HHS K23 AR068443NIAMS NIH HHS P60 AR056116
6 · The paper itself

Abstract

objectiveMicroRNA (miRNA) are small noncoding RNA that posttranscriptionally regulate gene expression and serve as potential mediators and markers of disease. Recently, plasma miR-24-3p and miR-125a-5p concentrations were shown to be elevated in rheumatoid arthritis (RA) and useful for RA diagnosis. We assessed the utility of 7 candidate plasma miRNA, selected for biological relevance, for RA diagnosis and use as markers of disease activity and subclinical atherosclerosis in RA.

methodsThe cross-sectional study included 168 patients with RA and 91 control subjects of similar age, race, and sex. Plasma concentrations of miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p were measured by quantitative PCR. Utility of plasma miRNA concentrations for RA diagnosis was assessed by area under the receiver-operating characteristic curve (AUROC). Associations between plasma miRNA concentrations and RA disease activity and coronary artery calcium score were assessed by Spearman correlations.

resultsPlasma concentrations of miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p were significantly increased in patients with RA. The highest AUROC for diagnosis of RA (AUROC = 0.725) was found in miR-24-3p, including among rheumatoid factor-negative patients (AUROC = 0.772). Among all patients with RA, the combination of miR-24-3p, miR-26a-5p, and miR-125a-5p improved the model modestly (AUROC = 0.747). One miRNA, miR-155-5p, was weakly inversely associated with swollen joint count (p = 0.024), but no other miRNA were associated with disease activity or coronary artery calcium score.

conclusionThe combination of miR-24-3p, miR-26a-5p, and miR-125a-5p had the strongest diagnostic accuracy for RA. Candidate miRNA had little or no association with RA disease activity or subclinical atherosclerosis.

Indexed as

AdultArea Under CurveArthritis, RheumatoidBiomarkersCardiovascular DiseasesComorbidityCoronary Artery DiseaseCross-Sectional StudiesFemaleHumansMaleMicroRNAsMiddle AgedReference ValuesRisk AssessmentROC CurveBiomarkersMicroRNAsATHEROSCLEROSISCARDIOVASCULAR RISKDIAGNOSISDISEASE ACTIVITYMICRORNARHEUMATOID ARTHRITIS

Identifiers

PMID26233505
PMCPMC4592411
OpenAlexW1943492589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.